Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivaltinostat plus capecitabine in metastatic pancreatic adenocarcinoma
NCT05249101Phase 2Active, not recruiting
- Sponsor
- CG Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivaltinostat in pancreatic adenocarcinoma (PDAC), sponsored by CG Pharmaceuticals. Started Aug 2022; status: active, not recruiting.
02
Drugs
ivaltinostat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05249101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05249101.